Turn.bio
Mountain View
About Turn.bio
Turn.bio is a biotechnology company developing drugs to reverse aging and age-related diseases. Utilizing a patented mRNA platform technology, ERA, the company is combating the effects of aging on the epigenome. The company’s proprietary mRNA platform technology, ERA and eTurna, a delivery platform specifically designed to enable nucleic acid therapeutics, combats the effects of aging in the epigenome, thus restoring optimal gene expression. It focuses on developing tailored therapies targeting indications in immune-related diseases like cancer and dermatological conditions, as well as therapies for ophthalmology, osteoarthritis, and the muscular system.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Funding stage: Early Stage Venture
- Last round: Series A (Mar 2024)
- Website: turn.bio
- Phone: +1 833 877 6246
Industries & Categories
Biotechnology, Genetics, Health Care, Life Science, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/turn-bio-2238832 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.